Literature DB >> 23548042

Reduction in thyroid perfusion after bevacizumab treatment.

Astrid A M van der Veldt1, Adriaan A Lammertsma, Egbert F Smit.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23548042     DOI： 10.1089/thy.2013.0147

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  4 in total

Review 1.  VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs.

Authors:  Yihai Cao
Journal:  Nat Rev Endocrinol       Date:  2014-07-22       Impact factor: 43.330

2.  The effect of intrathyroidal versus intraperitoneal bevacizumab on thyroid volume and vasculature flow in a rat model.

Authors:  Aaron Smith; Vikrum Thimmappa; John D Boughter; Christopher Vanison; Courtney B Shires; Merry Sebelik
Journal:  Gland Surg       Date:  2019-06

Review 3.  Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment.

Authors:  Hala Ahmadieh; Ibrahim Salti
Journal:  Biomed Res Int       Date:  2013-10-27       Impact factor: 3.411

4.  VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis.

Authors:  Jeon Yeob Jang; Sung Yong Choi; Intae Park; Do Young Park; Kibaek Choe; Pilhan Kim; Young Keum Kim; Byung-Joo Lee; Masanori Hirashima; Yoshiaki Kubota; Jeong-Won Park; Sheue-Yann Cheng; Andras Nagy; Young Joo Park; Kari Alitalo; Minho Shong; Gou Young Koh
Journal:  EMBO Mol Med       Date:  2017-06       Impact factor: 12.137
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.